Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.epidem.2021.100446 http://scihub22266oqcxt.onion/10.1016/j.epidem.2021.100446 33706041!7919530!33706041     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33706041&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Epidemics 2021 ; 35 (?): 100446 Nephropedia Template TP {{tp|p=33706041|t=2021. Modelling suggests ABO histo-incompatibility may substantially reduce SARS-CoV-2 transmission |pdf=|usr=}}{{33706041}} gab.com Text Modelling suggests ABO histo-incompatibility may substantially reduce SARS-CoV-2 transmission JO: Epidemics http://www.kidney.de/pget.php?&tw=1&pmid=33706041 #FOAvip Several independent datasets suggest blood type A is over-represented and type O under-represented among COVID-19 patients. However, blood group antigens appear not to be conventional susceptibility factors in that they do not affect disease severity, and the relative risk to non-O individuals is attenuated when population prevalence is high. Here, I model a scenario in which ABO transfusion incompatibility reduces the chance of a patient transmitting the virus to an incompatible recipient - thus in Western populations type A and AB individuals are "super-recipients" while type O individuals are "super-spreaders". This results in an offset in the timing of the epidemic among individuals of different blood types, and an increased relative risk to type A/AB patients that is most pronounced during early stages of the epidemic. However, once the majority of any given population is infected, the relative risk to each blood type approaches unity. Published data on COVID-19 prevalence from regions in the early stages of the SARS-CoV-2 epidemic suggests that if this model holds true, ABO incompatibility reduces virus transmissibility by at least 60 %. Exploring the implications of this model for vaccination strategies shows that paradoxically, targeted vaccination of either high-susceptibility type A/AB or "super-spreader" type O individuals is less effective than random vaccination at blocking community spread of the virus. Instead, the key is to maintain blood type diversity among the remaining susceptible individuals. Given the good agreement between this model and observational data on disease prevalence, the underlying biochemistry urgently requires experimental investigation. Twit Text FOAVip Modelling suggests ABO histo-incompatibility may substantially reduce SARS-CoV-2 transmission ????Epidemics http://www.kidney.de/pget.php?&tw=1&pmid=33706041 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33706041 #FOAvip English Wikipedia <ref>{{Cite pmid|33706041}}</ref> Modelling suggests ABO histo-incompatibility may substantially reduce SARS-CoV-2 transmission #MMPMID33706041 Ellis PJI Epidemics 2021[Jun]; 35 (?): 100446 PMID33706041show ga Several independent datasets suggest blood type A is over-represented and type O under-represented among COVID-19 patients. However, blood group antigens appear not to be conventional susceptibility factors in that they do not affect disease severity, and the relative risk to non-O individuals is attenuated when population prevalence is high. Here, I model a scenario in which ABO transfusion incompatibility reduces the chance of a patient transmitting the virus to an incompatible recipient - thus in Western populations type A and AB individuals are "super-recipients" while type O individuals are "super-spreaders". This results in an offset in the timing of the epidemic among individuals of different blood types, and an increased relative risk to type A/AB patients that is most pronounced during early stages of the epidemic. However, once the majority of any given population is infected, the relative risk to each blood type approaches unity. Published data on COVID-19 prevalence from regions in the early stages of the SARS-CoV-2 epidemic suggests that if this model holds true, ABO incompatibility reduces virus transmissibility by at least 60 %. Exploring the implications of this model for vaccination strategies shows that paradoxically, targeted vaccination of either high-susceptibility type A/AB or "super-spreader" type O individuals is less effective than random vaccination at blocking community spread of the virus. Instead, the key is to maintain blood type diversity among the remaining susceptible individuals. Given the good agreement between this model and observational data on disease prevalence, the underlying biochemistry urgently requires experimental investigation. |*ABO Blood-Group System[MESH] |*Blood Group Incompatibility/blood/epidemiology[MESH] |*Models, Theoretical[MESH] |COVID-19/blood/epidemiology/*transmission[MESH] |Disease Susceptibility/blood/epidemiology[MESH] |Humans[MESH] |Prevalence[MESH] |Risk[MESH] |SARS-CoV-2[MESH]Modelling suggests ABO histo-incompatibility may substantially reduce (epmc).pdf DeepDyve Pubget Overpricing